<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00296023</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000463724</org_study_id>
    <secondary_id>UCSF-98251</secondary_id>
    <secondary_id>UCSF-9805</secondary_id>
    <secondary_id>UCSF-H9996-15837-06</secondary_id>
    <nct_id>NCT00296023</nct_id>
  </id_info>
  <brief_title>Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer</brief_title>
  <official_title>Low-Dose Allogeneic Peripheral Blood Stem Cell Transplantation for High-Risk Low Grade Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor&#xD;
      bone marrow or peripheral blood stem cell transplant helps stop the growth of cancer cells.&#xD;
      It also stops the patient's immune system from rejecting the donor's stem cells. The donated&#xD;
      stem cells may replace the patient's immune system and help destroy any remaining cancer&#xD;
      cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor&#xD;
      lymphocyte infusion) after the transplant may help increase this effect. Sometimes the&#xD;
      transplanted cells from a donor can also make an immune response against the body's normal&#xD;
      cells. Giving antithymocyte globulin before transplant and methotrexate and tacrolimus after&#xD;
      the transplant may stop this from happening.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects of donor stem cell transplant in&#xD;
      treating older or frail patients with hematologic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety of non-myeloablative allogeneic peripheral blood stem cell&#xD;
           transplantation, in terms of regimen-related organ toxicity and toxicity from acute&#xD;
           graft-vs-host disease (GVHD), in older or medically frail patients with high-risk&#xD;
           indolent hematologic malignancies.&#xD;
&#xD;
        -  Determine overall survival, disease-free survival, and relapse risk at 1, 2, and 3 years&#xD;
           post-transplantation in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the engraftment of donor hematopoiesis at 6 weeks, 3 and 6 months, and 1 year&#xD;
           post-transplantation in these patients.&#xD;
&#xD;
        -  Determine the incidence and severity of chronic GVHD in older and medically infirm&#xD;
           patients treated with this regimen.&#xD;
&#xD;
        -  Determine the safety and efficacy of collecting peripheral blood stem cells from older&#xD;
           donors (age &gt; 60 years).&#xD;
&#xD;
        -  Determine the need and efficacy of donor lymphocyte infusions in patients with residual&#xD;
           disease after transplant.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
        -  Non-myeloablative preparative regimen:Patients receive fludarabine IV over 30 minutes on&#xD;
           days -7 to -3, busulfan IV over 2 hours every 8 hours on days -4 and -3, and&#xD;
           anti-thymocyte globulin IV over 8 hours on days -4 to -1.&#xD;
&#xD;
        -  Transplantation: Patients undergo allogeneic peripheral blood stem cell transplantation&#xD;
           on day 0. Patients receive filgrastim (G-CSF) subcutaneously beginning on day 6 and&#xD;
           continuing until blood counts recover.&#xD;
&#xD;
        -  Graft-vs-host disease (GVHD) prophylaxis: Patients receive tacrolimus orally every 12&#xD;
           hours or IV continuously beginning on day -2 and continuing until day 90, followed by a&#xD;
           taper until day 180. Patients also receive methotrexate IV over 15-30 minutes on days 1,&#xD;
           3, 6, and 11.&#xD;
&#xD;
        -  Donor lymphocyte infusions (DLIs): Patients with residual disease ≥ 6 months&#xD;
           post-transplantation who are off immunosuppression for ≥ 30 days with no evidence of&#xD;
           GVHD may receive DLIs. DLIs are administered ≥ 12 weeks apart in the presence of&#xD;
           persistent disease, absence of severe (grade 3-4) GVHD, and absence of persistent GVHD&#xD;
           after the first DLI.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically for 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1999</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity and survival</measure>
    <time_frame>up to 36 months post transplant</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>stem cell transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <arm_group_label>stem cell transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <arm_group_label>stem cell transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
    <arm_group_label>stem cell transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <arm_group_label>stem cell transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <arm_group_label>stem cell transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <arm_group_label>stem cell transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <arm_group_label>stem cell transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>nonmyeloablative allogeneic hematopoietic stem cell transplantation</intervention_name>
    <arm_group_label>stem cell transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <arm_group_label>stem cell transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of a high-risk indolent hematologic malignancy meeting the following&#xD;
             criteria:&#xD;
&#xD;
               -  Chronic lymphocytic leukemia (CLL) meeting 1 of the following criteria:&#xD;
&#xD;
                    -  In second or subsequent remission&#xD;
&#xD;
                    -  Failed to achieve a complete remission (CR) after chemotherapy&#xD;
&#xD;
               -  Non-Hodgkin's lymphoma (NHL) meeting 1 of the following criteria:&#xD;
&#xD;
                    -  Low-grade NHL meeting 1 of the following criteria:&#xD;
&#xD;
                         -  Standard-risk disease in second or subsequent remission&#xD;
&#xD;
                         -  Standard-risk disease and failed to achieve a CR after chemotherapy&#xD;
&#xD;
                         -  In first or subsequent remission with adverse International Prognostic&#xD;
                            Index (IPI) prognostic features, as defined by the presence of ≥ 3 of&#xD;
                            the following:&#xD;
&#xD;
                              -  Age &gt; 60 years&#xD;
&#xD;
                              -  Tumor stage III or IV&#xD;
&#xD;
                              -  Extranodal disease at &gt; 1 site&#xD;
&#xD;
                              -  ECOG performance status ≥ 2&#xD;
&#xD;
                              -  Serum lactic dehydrogenase (LDH) &gt; upper limit of normal (ULN)&#xD;
&#xD;
                    -  Intermediate- or high-grade NHL meeting 1 of the following criteria:&#xD;
&#xD;
                         -  In second or subsequent remission&#xD;
&#xD;
                         -  Failed to achieve a CR after initial chemotherapy&#xD;
&#xD;
               -  Waldenstrom's macroglobulinemia meeting 1 of the following criteria:&#xD;
&#xD;
                    -  In second or subsequent remission&#xD;
&#xD;
                    -  Failed to achieve a CR after initial chemotherapy&#xD;
&#xD;
               -  Multiple myeloma meeting 1 of the following criteria:&#xD;
&#xD;
                    -  In first or subsequent remission&#xD;
&#xD;
                    -  Failed to achieve a CR after initial chemotherapy&#xD;
&#xD;
               -  Myeloproliferative disorders, including any of the following:&#xD;
&#xD;
                    -  Chronic myelogenous leukemia in first or subsequent chronic phase&#xD;
&#xD;
                    -  Myelofibrosis&#xD;
&#xD;
                    -  Essential thrombocytopenia that is poorly responsive to standard therapy&#xD;
&#xD;
                    -  Polycythemia vera that is poorly responsive to standard therapy or is in&#xD;
                       spent phase&#xD;
&#xD;
               -  Prolymphocytic leukemia meeting 1 of the following criteria:&#xD;
&#xD;
                    -  In first or subsequent remission&#xD;
&#xD;
                    -  Failed to achieve a CR after initial chemotherapy&#xD;
&#xD;
               -  Mantle cell lymphoma meeting 1 of the following criteria:&#xD;
&#xD;
                    -  In first or subsequent remission&#xD;
&#xD;
                    -  Failed to achieve a CR after initial chemotherapy&#xD;
&#xD;
               -  Hodgkin's lymphoma meeting the following criteria:&#xD;
&#xD;
                    -  In second or subsequent remission&#xD;
&#xD;
                         -  Prior remission duration &gt; 6 months&#xD;
&#xD;
                    -  No radiation therapy as the only prior primary therapy&#xD;
&#xD;
               -  Myelodysplastic syndromes (MDS) meeting 1 of the following criteria:&#xD;
&#xD;
                    -  Refractory anemia with excess blasts (RAEB)&#xD;
&#xD;
                    -  RAEB in transformation&#xD;
&#xD;
                    -  Chronic myelomonocytic leukemia&#xD;
&#xD;
                    -  Any MDS with transfusion dependence&#xD;
&#xD;
                    -  Any MDS with ≥ 2 significant infections&#xD;
&#xD;
               -  Acute myeloid leukemia in morphologic remission&#xD;
&#xD;
          -  In CR or partial remission or stabilization of disease after standard chemotherapy&#xD;
&#xD;
               -  No progressive or refractory disease&#xD;
&#xD;
          -  Not eligible for standard allogeneic bone marrow transplantation&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
               -  Age 60 to 75 years old AND no co-morbid illness&#xD;
&#xD;
               -  Younger patients with any of the following comorbidities:&#xD;
&#xD;
                    -  Decreased cardiac ejection fraction&#xD;
&#xD;
                    -  Pulmonary dysfunction&#xD;
&#xD;
                    -  Elevated liver function tests&#xD;
&#xD;
                    -  Hepatitis C infection&#xD;
&#xD;
                    -  Poor performance status&#xD;
&#xD;
          -  Sibling or related donor available&#xD;
&#xD;
               -  Matched ≥ 5/6 HLA loci (A, B, and DR) NOTE: A new classification scheme for adult&#xD;
                  non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of &quot;indolent&quot; or&#xD;
                  &quot;aggressive&quot; lymphoma will replace the former terminology of &quot;low&quot;,&#xD;
                  &quot;intermediate&quot;, or &quot;high&quot; grade lymphoma. However, this protocol uses the former&#xD;
                  terminology.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Creatinine &lt; 2.0 mg/dL&#xD;
&#xD;
          -  Creatinine clearance &gt; 40 mL/min&#xD;
&#xD;
          -  Ejection fraction &gt; 30% by echocardiogram or MUGA&#xD;
&#xD;
          -  Bilirubin &lt; 3.0 mg/dL (if total bilirubin is elevated and Gilbert's disease is&#xD;
             suspected, direct bilirubin must be normal)&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 4 times ULN&#xD;
&#xD;
          -  AST &lt; 4 times ULN&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Hepatitis B and/or C virus allowed if a liver biopsy (performed within the past 3&#xD;
             months) shows ≤ grade 2 inflammation&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas G. Martin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Willis Navarro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles A. Linker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alta Bates Comprehensive Cancer Center</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>February 23, 2006</study_first_submitted>
  <study_first_submitted_qc>February 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2006</study_first_posted>
  <last_update_submitted>October 2, 2012</last_update_submitted>
  <last_update_submitted_qc>October 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>primary myelofibrosis</keyword>
  <keyword>polycythemia vera</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <keyword>stage II adult Hodgkin lymphoma</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>Waldenström macroglobulinemia</keyword>
  <keyword>essential thrombocythemia</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

